The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

An extraordinary series of discoveries about chronic myeloid leukemia (CML) has made this
disease a model of the way in which bench and bedside research can unite and culminate …

Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …

Abstract BCR-ABL1 kinase domain (KD) mutation status is considered to be an important
element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do …

Abstract Treatment of chronic myeloid leukemia has improved significantly with the
introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines based on …

Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor
cells into patients with hematologic disorders with the goal of re-establishing normal …

The purpose of this study was to analyze medical late effects among patients with chronic
myeloid leukemia (CML) treated with hematopoietic cell transplantation (HCT). Subjects …

MHC class I chain-related molecules (MIC) participate in immune surveillance of cancer
through engagement of the NKG2D-activating receptor on NK and T cells. Decreased …

The impact of imatinib mesylate (IM) treatment for chronic myeloid leukemia (CML) on
subsequent allogeneic transplantation is uncertain. To better understand this relationship …

We identified 243 patients with Philadelphia (Ph) chromosome–positive chronic myeloid
leukemia (CML) who had BCR-ABL transcripts monitored by quantitative reverse …